FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
April 04 2024 - 8:31AM
FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a
clinical-stage biotechnology company with 150+ patents issued and
pending for the development of therapeutics and potential cures for
chronic diseases using fibroblasts and fibroblast-derived
materials, announced today data from its latest study in a diabetes
mouse model on the potential therapeutic efficacy of dermal
fibroblast spheroids in treating chronic wounds. These findings
will be presented via an oral and poster presentation at the
Advanced Wound Care Summit USA in Boston, MA, April 16-17.
Diabetic foot ulcers (DFUs) are prevalent in individuals with
diabetes, with approximately 33 million people impacted globally.
DFUs pose significant challenges for patients and the healthcare
system due to impaired healing mechanisms associated with
hyperglycemia, cellular senescence, and other comorbidities
associated with diabetes. FibroBiologics' research aims to address
this issue by investigating the potential of using human dermal
fibroblast (HDF) spheroids in promoting and accelerating the wound
healing process in diabetic patients.
The study, led by a team of researchers including
FibroBiologics’ Chief Scientific Officer, Hamid Khoja, Ph.D.,
utilized a diabetic mouse model to evaluate the therapeutic effects
of HDF spheroids on mice with wounds resembling DFUs.
Key findings from the study include:
- Acceleration of
wound healing with a 60% decrease in relative wound area within 4
days post-treatment with a single administration of HDF spheroids
compared to standard of care treatment control.
- Upregulation of pro-inflammatory
cytokines such as interferon-gamma (IFN-γ), interleukins IL-1), and
tumor necrosis factor-alpha (TNF-α), along with anti-inflammatory
cytokines IL-6 and IL-10, indicating modulation of the wound
microenvironment conducive to healing.
- Increased levels of vascular
endothelial growth factors (VEGF) and endothelial growth factor
receptors (EGFR), suggesting enhanced revascularization and
re-epithelialization in HDF-treated wounds.
- Immunohistochemical analysis revealing
the presence of markers indicative of fibroblast and endothelial
proliferation, active cell proliferation, angiogenesis, and
macrophage proliferation in HDF-treated wounds.
"These results support the potential of HDF spheroids to
expedite the healing process of chronic wounds associated with
diabetes," said Dr. Khoja. "Our findings underscore the importance
of further exploration and development of fibroblast spheroid-based
therapies for clinical applications, particularly in patients with
diabetic foot ulcers."
Details of the presentations are as follows:
Oral Presentation:
Presentation Title: Fibroblast
Spheroid-mediated Accelerated Chronic Wound Healing in a Diabetic
Mouse ModelPresenter: Hamid Khoja, Ph.D.,
Chief Scientific Officer, FibroBiologicsSession
Title: Research and Development -
BiologicsSession Date and Time: April 16,
2024, at 12:30 p.m. Eastern Standard Time
Poster Presentation:
Presentation Title: Dermal Fibroblast
Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse
ModelPresenter: Subhiksha Raghuram, MS, MD,
Associate Scientist, FibroBiologicsPoster
Session: Available Virtually
For more information, please visit FibroBiologics' website or
email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking
Statements
This communication contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include information concerning the
potential therapeutic efficacy of dermal fibroblast spheroids,
possible modulation of the wound microenvironment conducive to
healing, enhanced revascularization and re-epithelialization in
HDF-treated wounds, the possibility of fibroblast and endothelial
proliferation, active cell proliferation, angiogenesis, and
macrophage proliferation in HDF-treated wounds, and our
expectations regarding plans for our current and future product
candidates and programs. These forward-looking statements are not
guarantees of future performance, conditions or results, and
involve a number of known and unknown risks, uncertainties,
assumptions and other important factors, many of which are outside
FibroBiologics' management's control, that could cause actual
results to differ materially from the results discussed in the
forward-looking statements, including those set forth under the
caption "Risk Factors" and elsewhere in FibroBiologics' annual,
quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form
8-K) as filed or furnished with the SEC and any subsequent public
filings. Copies are available on the SEC's
website, www.sec.gov. These risks, uncertainties, assumptions
and other important factors include, but are not limited to: (a)
expectations regarding the initiation, progress and expected
results of our R&D efforts and preclinical studies; and (b) the
unpredictable relationship between R&D and preclinical results
and clinical study results. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and FibroBiologics
assumes no obligation and, except as required by law, does not
intend to update or revise these forward-looking statements,
whether as a result of new information, future events, or
otherwise. FibroBiologics gives no assurance that it will achieve
its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a cell therapy and
regenerative medicine company developing a pipeline of treatments
and seeking potential cures for chronic diseases using fibroblast
cells and fibroblast-derived materials. FibroBiologics holds 150+
US and internationally issued patents/patents pending across
various clinical pathways, including disc degeneration,
orthopedics, multiple sclerosis, wound healing, reversing organ
involution, and cancer. FibroBiologics represents the next
generation of medical advancement in cell therapy. For more
information, visit www.FibroBiologics.com.
Investor Relations:Nic Johnson or Harrison Seidner, Ph.D.Russo
Partners(646) 942-5599fibrobiologicsIR@russopr.com
Media Contact:Liz PhillipsRusso Partners(347)
956-7697Elizabeth.phillips@russopartnersllc.com
General Inquiries:info@fibrobiologics.com
FibroBiologics (NASDAQ:FBLG)
Historical Stock Chart
From Jun 2024 to Jul 2024
FibroBiologics (NASDAQ:FBLG)
Historical Stock Chart
From Jul 2023 to Jul 2024